ing bone pain of patients with breast cancer and osseous metastasis

group). The analgesic effect, remission of bone metastases, and quality of life of patients in the three groups were observed before and after treatment. Side effect was also monitored. Results: In the combination group, the overall pain relief rate and the increase rate of life quality score were 92.9% (26/28) and 78.6% (22/28), respectively. The combination group was statistically significantly different from the two single-treatment groups (P<0.05). The effective rate of metastatic lesions was 46.4% (13/28) in the combination group, which was significantly higher than that in the